

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug platforms</b>			
Prolonging half-life of embryonic stem cell (ESC)-derived platelets with metalloproteinase inhibitors	Cell-culture and mouse studies suggest that metalloproteinase inhibitors may help in generating platelets from ESCs to treat thrombocytopenia and other hematological diseases. Murine ESC-derived platelets treated with the metalloproteinase inhibitor GM6001 had higher fibrinogen binding and formed larger thrombi than platelets in vehicle-treated controls. In mice with thrombocytopenia, GM6001-treated platelets had a longer half-life than those in vehicle-treated controls. Next steps include reproducing the observed effects in human ESC-derived platelets and developing methods to produce them in sufficient quantity for clinical use.	Patent pending for generation of platelets from pluripotent stem cells; available for licensing from the University of Tokyo Technology Licensing Organization	Hicks, S.N. <i>et al. J. Exp. Med.</i> ; published online July 28, 2008; doi:10.1084/jem.20071482 <b>Contact:</b> Hiromitsu Nakauchi, University of Tokyo, Tokyo, Japan e-mail: <a href="mailto:keto@ims.u-tokyo.ac.jp">keto@ims.u-tokyo.ac.jp</a> <b>Contact:</b> Koji Eto, same affiliation as above e-mail: <a href="mailto:nakauchi@ims.u-tokyo.ac.jp">nakauchi@ims.u-tokyo.ac.jp</a>